![Hoe eenvoudige semantiek onze AI-citaties met 642% verhoogde [Nieuwe resultaten]](https://www.pharmamarketeer.nl/wp-content/uploads/2026/01/719-370x300.jpg)
British drugmaker AstraZeneca Plc said on Monday the European Commission approved its diabetes drug Forxiga for use as an oral supplement to insulin in adults with a rare type of the disease.
De toekomst van content is context #spon
Online personalisatie is de volgende stap voor marketeers en ondernemers die meer uit hun (mobiele) website willen halen. “De toekomst van content is context”, zegt Martin van Kranenburg, docent bij Beeckestijn Business...
Pfizer and Merck discontinue Phase 3 avelumab ovarian cancer trial
Pfizer and Merck KGaA have chosen to discontinue the Phase 3 JAVELIN trial looking into avelumab in combination with chemotherapy as a treatment for advanced ovarian cancer. The discontinued trial sought to investigate...
FDA approves first paediatric treatment for intra-abdominal and urinary tract infections in over 10 years
Allergan has revealed that Avycaz (ceftazidime and avibactam) has been awarded an expansion of its label by the FDA to include the treatment of complicated intra-abdominal infections (cIAI) in combination with...
FDA approves first-ever postpartum depression therapy: Sage Therapeutics’ Zulresso
The FDA has announced its decision to approve Sage Therapeutics’ intraveneous injection Zulresso (brexanolone), marking the first authorisation of a treatment for postpartum depression (PPD) in adult women in the...
FDA puts multiple myeloma trial on hold after patient deaths
The FDA has placed a partial clinical hold on studies of multiple myeloma treatment Venclexta/Venclyxto (venetoclax) following a number of patient deaths in a late stage study. AbbVie who are developing the drug with...
Two-drug combinations containing calcium channel blocker significantly lowers BP
In the largest randomized controlled trial of treatment for high blood pressure ever conducted in sub-Saharan Africa, two frontline two-drug combinations that included the long-acting calcium channel blocker...
Wat marcom-superhelden dan wel doen
Wat is het basisrecept voor menselijke, duurzame marketingcommunicatie? Stoppen met kwebbelen, beginnen met luisteren. De enige oplossing voor marcom is content maken en optimaliseren die gebruikers en hun taken, vragen...
Allergy Therapeutics’ adjuvanted birch allergoid drug shocks with Phase 3 failure
UK-based biotech firm Allergy Therapeutics has been left disappointed after it became evident that its adjuvanted birch allergoid product failed its primary endpoint in the treatment of birch-pollen induced seasonal...
Rant Alert: Content Marketers Must Up Their Data Game
Four of five marketers aren’t comfortable making sense of data, a recent survey says. Yet, they have access to powerful self-service marketing analytics tools. How can you get more proficient with data? Start with this...
[column] Contentmarketing vraagt om talent, inzicht en kunde
‘Wat moet je deze week weer klaarspelen?’ vraag ik aan mijn dochter die net aan een nieuwe baan is begonnen. ‘Leren, veel leren,’ zegt ze.
Roche scores two EU approvals in haemophilia and rare autoimmune disease
The European Commission (EC) has approved Roche’s haemophilia treatment Hemlibra (emicizumab). The approval comes as the EC approved Roche’s MabThera (rituximab) for the rare autoimmune disease pemphigus vulgaris...
Sanofi and Regeneron’s Praluent approved in Europe to reduce CV risk
Sanofi and Regeneron’s Praluent (alirocumab) has been awarded approval by the European Commission, it has emerged, as a therapy to reduce cardiovascular risk in patients with established atherosclerotic CV disease...
Positief advies uitbreiding indicatie dupilumab
De Committee for Medicinal Products for Human Use (CHMP) heeft een positief advies gegeven over uitbreiding van de indicatie voor dupilumab (Dupixent). Het geneesmiddel is nu – naast een indicatie voor matig tot ernstig...
MSD’s Keytruda/chemo combo nabs EU approval in first-line metastatic squamous lung cancer
MSD’s anti-PD-L1 therapy Keytruda (pembrolizumab) has been awarded marketing authorisation in Europe for the first-line treatment of adult patients with metastatic squamous non-small cell lung cancer (NSCLC) when used...
How to Be the Content in the Enviable Google Answer Box
Voice searchers hear only one answer. Visual searchers are inclined to take the first answer. How can your content get that premium placement? Follow these six steps to increase the likelihood you’ll be featured in...
Nieuwe vergunning voor sotagliflozine
Sotagliflozine (Zynquista) kreeg een positief advies voor een nieuwe handelsvergunning van de Committee for Medicinal Products for Human Use (CHMP). Het middel is bestemd als toevoeging op insulinetherapie voor bepaalde...
